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Abstract 
Older adults are frequently prescribed atypical antipsychotic drugs and may be at a risk for 
kidney-related adverse events. This population-based retrospective cohort study examined 
the 90-day risk of acute kidney injury (AKI) and the potential reasons for AKI in 96,471 
matched pairs of older adults who received and who did not receive a new atypical 
antipsychotic drug prescription from 2003 to 2011 in Ontario. Atypical antipsychotic drug 
use was associated with a higher risk of hospitalization with AKI (relative risk (RR) 2.06 
[95% confidence interval (CI) 1.85–2.29]). The drug use was also associated with potential 
reasons for AKI including hypotension (RR 2.16 [95% CI 1.81–2.57]), acute urinary 
retention (RR 2.15 [95% CI 1.78–2.60]), and neuroleptic malignant 
syndrome/rhabdomyolysis (RR 1.44 [95% CI 1.06–1.96]). Residual confounding is unlikely 
to explain the observed associations entirely. This knowledge informs prescribing practice 
and may help identify a drug-induced reason for AKI. 
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Chapter 1  
1 Introduction 
Atypical antipsychotic drugs (quetiapine, risperidone, and olanzapine) are frequently 
prescribed to older adults and the incidence of its use in the population continues to 
increase.1,2 In many jurisdictions these drugs are used to manage behavioural symptoms 
of dementia, which is not an approved indication.2–5 Safety concerns have also been 
raised about the use of these drugs in older adults.3,4,6,7 Acute kidney injury (AKI; a rapid 
decline in kidney function) has been attributed to atypical antipsychotic drugs in several 
case reports.8–12 Potential reasons for AKI include hypotension, acute urinary retention, 
and neuroleptic malignant syndrome/rhabdomyolysis. The antagonistic properties of 
atypical antipsychotic drugs against alpha-adrenergic, muscarinic acetylcholine, 
serotonin, and dopamine receptors contributes to the adverse effects that may cause 
AKI.8–30 Acute myocardial infarction and ventricular arrhythmias have also been 
attributed to these drugs, and acute cardiac events can lead to hemodynamic 
derangements and poor renal perfusion.31,32 However, no clinical or epidemiologic 
studies have quantified the risk of AKI from atypical antipsychotic drugs. This 
information would add to growing knowledge of potential adverse events from this drug 
class – the U.S. Food and Drug Administration now warns of an increased risk of death in 
older patients treated with these drugs versus placebo from analyses of placebo-
controlled trials (averaging 10 weeks in duration).3 We conducted a population-based 
retrospective matched cohort study of older adults in Ontario, Canada to characterize the 
90-day risk of hospitalization with AKI associated with new atypical antipsychotic drug 
use versus non-use. Moreover, we explored the potential reasons by which the kidney 
injury may occur from the use of these drugs. 
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Chapter 2  
2 Literature Review 
 
2.1 Acute kidney injury (AKI) 
AKI is a sudden decline in kidney function, often following insults that cause structural 
or functional alterations in the kidneys.33,34 The rapid loss in kidney function results in 
accumulation of nitrogenous metabolic waste products including serum creatinine and 
urea.  
Measuring changes in serum creatinine concentration is a laboratory-based clinical tool 
widely used to detect AKI.35–37 AKI is defined as an absolute rise in serum creatinine 
concentration by 26.5 µmol/L or more within 48 hours or a relative rise by 50% or more 
within seven days.37 
The population-based incidence rate of AKI is 408.5 cases per 100,000 person-years and 
is increasing by 10% each year.38,39 AKI is also a frequent clinical challenge with 
incidence of 19.2 to 23.8 cases per 1000 hospitalizations.40,41 The mortality rate of 
hospitalized patients with AKI approximates 20.3 to 28.1%.42 AKI is associated with 
increased risks of developing permanent kidney failure (end-stage kidney disease) and in-
hospital mortality.40,43,44 AKI poses a financial burden to the healthcare system as patients 
with the kidney injury have longer length of hospital stay and higher healthcare costs.40,43 
 
2.2 Risk factors for AKI 
A number of demographic factors, comorbid conditions, and certain medications have 
been associated with AKI. 
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2.2.1 Age 
Older age is a risk factor for AKI due to the age-related reduction in kidney function 
reserve and compromised ability of the kidneys to withstand acute insults.45,46 A 
population-based study conducted in the U.S. observed progressively higher incidences 
of AKI with increasing age (less than 50 years: 78.0 cases per 100,000 person-years; 50 
to 59 years: 320.0 cases per 100,000 person-years; 60 to 69 years: 814.8 cases per 
100,000 person-years; 70 to 79 years: 1809.1 cases per 100,000 person-years; 80 years or 
older: 3545.4 cases per 100,000 person-years).38 Moreover, a prospective cohort study of 
1,411 critically ill patients showed that those aged 65 years and older were more likely to 
develop AKI compared to those younger than 65 years (OR 1.50 [95% CI 1.16–1.92]; P 
= 0.002).47 
2.2.2 Sex 
Previous studies have implicated male sex with a higher risk of AKI.38,48 A population-
based study of 3,787,410 U.S. adults found a higher incidence of AKI in men than 
women (443.1 cases per 100,000 person-years versus 330.4 cases per 100,000 person-
years).38 Bagshaw et al.48 showed that men aged 65 years and older were at a 
significantly greater risk of intensive care unit admission with AKI compared to women 
of same age group (RR 2.2 [95% CI 1.5–3.2]; P < 0.0001). 
2.2.3 Chronic kidney disease (CKD) 
Measuring estimated glomerular filtration rate (GFR) is a widely used, serum creatinine-
based assessment of baseline kidney function.49 Briefly, GFR is the volume of fluid 
filtered through the kidney glomeruli per unit time, based on serum creatinine 
clearance.50,51 A normal GFR is greater than 80 mL/min/1.73 m2, while patients with a 
GFR less than 10 mL/min/1.73 m2 frequently need ongoing dialysis treatments to 
maintain their life.49,50 Chronic kidney disease (CKD) is defined as abnormalities of 
kidney structure or function that is prolonged for greater than three months.49 CKD is 
categorized into six stages according to its severity (i.e. the degree to which GFR is 
reduced; stages 1, 2, 3a, 3b, 4, and 5; from less to more severe).51  
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CKD is a potent risk factor for AKI as the chronic condition leaves patients more 
vulnerable to acute insults to the kidneys.37,52 A population-based surveillance performed 
in Alberta showed that patients with a history of CKD had a significantly higher risk of 
intensive care unit admission with AKI compared to patients without such a history (RR 
4.9 [95% CI 3.5–6.8]; P < 0.0001).48 Two retrospective cohort studies demonstrated a 
graded relationship between the severity of CKD and the risk of hospitalization with 
AKI.53,54 Pannu et al.53 demonstrated that, compared to patients with CKD Stage 3a, 
those with more advanced stages of CKD were more likely to develop AKI. Patients with 
CKD Stage 3b, 4, and 5 had ORs for hospitalization with AKI of 2.9 (95% CI 2.7–3.1), 
6.2 (95% CI 5.7–6.8), and 18.3 (95% CI 16.5–20.3), respectively.53 James et al.54 had 
similar findings from a cohort of 920,985 patients with CKD. In their study, patients with 
CKD Stage 3b, 4, and 5 had respective rate ratios for hospitalization with AKI of 2.3 
(95% CI 2.1–2.4), 5.6 (95% CI 5.1–6.2), and 13 (95% CI: 11–15) compared to patients 
with CKD Stage 3a.54 
2.2.4 Diabetes mellitus 
Diabetes mellitus, characterized by the chronic elevation of blood glucose level, is one of 
the leading causes of kidney disease.55–57 The scarring of kidney nephrons in diabetes 
mellitus contributes to the reduction of kidney function.55–57 A population-based 
surveillance study showed that adults diagnosed with diabetes mellitus had a significantly 
greater risk of intensive care unit admission with AKI compared to those without such a 
diagnosis (RR 10.3 [95% CI 7.7–13.6]; P < 0.0001).48 Moreover, a case-control study 
that included 1,764 patients who acquired AKI and 600,820 patients who did not acquire 
AKI during hospitalization suggested that diabetes mellitus is a risk factor for AKI.58 In 
the study, patients who developed AKI were more likely to have pre-existing diabetes 
mellitus compared to patients who did not develop the kidney injury (OR 2.07 [95% CI 
1.86–2.30]).58 
2.2.5 Cardiovascular disease 
Normal kidney function is dependent on sufficient perfusion of the kidneys by the 
cardiovascular system.33,59 Hemodynamic disturbances that arise from cardiovascular 
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disorders may reduce renal perfusion and lead to decline in kidney function.33,59 
Moreover, prolonged reduction in renal perfusion can lead to structural changes in the 
kidneys.33,59 Bagshaw et al.48 showed that adults with a history of heart disease had a 
significantly increased risk of intensive care unit admission with AKI compared to adults 
without such a history (RR 24.0 [95% CI 18.5–31.2]; P < 0.0001). In the same study, 
individuals with a history of stroke had with a significantly higher risk of AKI than those 
without such a history (RR 22.0 [95% CI 15.6–31.0]; P < 0.0001).48 Poor left ventricular 
function has also been identified as a risk factor for AKI following cardiac surgery.60 A 
prospective cohort study of critically ill patients demonstrated that individuals with heart 
failure were significantly more likely to acquire AKI compared to those without heart 
failure (OR 2.18 [95% CI 1.12–4.44]; P = 0.02).47 A case-control study of hospitalized 
patients found patients who suffered AKI were more likely to have pre-existing 
congestive heart failure than patients who did not suffer the kidney injury (OR 9.0 [95% 
CI 2.1–38.9]; P < 0.0001).61 Hsu et al.58 performed a case-control study of 602,584 
hospitalized patients and found patients who acquired AKI had higher odds of having a 
history of hypertension compared to patients who did not acquire the kidney injury (OR 
1.41 [95% CI 1.25–1.58]).  
2.2.6 Liver disease 
Liver diseases such as cirrhosis predispose patients to AKI. Reasons include decreased 
hyperdynamic circulation and decreased renal perfusion from blood volume depletion.62 
A prospective cohort study conducted in an intensive care setting found patients with 
with cirrhosis had a significantly higher odds of developing AKI compared to those 
without cirrhosis (OR 2.18 [95% CI 1.16–4.10]; P = 0.01).47 
2.2.7 Medications 
A number of commonly prescribed medications can predispose patients to AKI.33,59,63,64 
Angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers 
(ARBs), diuretics, and calcium channel blockers have anti-hypertensive properties and 
AKI may occur with the use of these medications due to decreased renal perfusion.64,65 
Moreover, the use of ACE inhibitors and ARBs can lead to reduced GFR due to their 
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ability to decrease glomerular pressure by down-regulating the synthesis and activity of 
angiotensin II.64,65 The use of non-steroidal anti-inflammatory drugs (NSAIDs) may also 
precipitate AKI.66 NSAID-induced AKI has been reported in patients with pre-existing 
kidney dysfunction, congestive heart failure, hypertension, or liver disease.67 A case-
control study of 360 hospitalized patients found those who suffered AKI were 
significantly more likely to have used ACE inhibitors, diuretics, or NSAIDs compared to 
those who did not suffer the kidney injury (OR 2.0 [95% CI 1.2–3.6]; P = 0.014).68 
Lipid lowering drug 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors 
(statins) may lead to rhabdomyolysis; a severe muscle injury characterized by the 
breakdown of skeletal muscles.69 The destruction of skeletal muscles results in the release 
of their contents, such as myoglobin, into the systemic circulation.69 Myoglobin is 
nephrotoxic and may lead to AKI.69,70 The U.S. Food and Drug Administration warned of 
the increased risk of myopathy associated with high dose statin based on the results of a 
randomized controlled trial.71,72 In the randomized trial, 52 patients (0.9%) who received 
high dose statin versus one patient (0.02%) patients who received low dose statin 
developed myopathy.72 In the same trial, 22 patients (0.4%) who received high dose statin 
versus no patient who received low dose statin developed rhabdomyolysis.72 In chart 
reviews of patients hospitalized with rhabdomyolysis, statin use contributed to 4 to 13% 
of the muscle injury.23,73  
 
2.3 Atypical antipsychotic drugs and older adults 
Atypical antipsychotic drugs (quetiapine, risperidone, and olanzapine) are psychoactive 
medications originally approved for the treatment of schizophrenia and bipolar disorder.74 
Although their mechanism of action is not entirely clear, the antipsychotic property of the 
drugs has been attributed to brief blockade of dopamine receptors in the central nervous 
system characterized by rapid dissociation from the receptors.75 Since their introduction 
in the 1990s, atypical antipsychotic drugs have largely replaced conventional 
antipsychotic drugs (the older class of antipsychotic drugs) due to their improved safety 
and efficacy profiles.1,76 Unlike conventional antipsychotic drugs, atypical antipsychotic 
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drugs produce minimal extrapyramidal side effects and improve both positive and 
negative symptoms of psychosis.77–79 These favourable characteristics of atypical 
antipsychotic drugs have been accredited to their ability to antagonize both dopamine and 
serotonin receptors in the central nervous system.78,79 
In many jurisdictions, atypical antipsychotic drugs are both frequently and increasingly 
prescribed to older adults.2,5 In 2002, the prevalence of antipsychotic drug prescription 
was 3% in Ontario residents 65 years and older and atypical antipsychotic drugs 
accounted for 82.5% of all antipsychotic drugs dispensed.1 Risperidone was the most 
commonly prescribed atypical antipsychotic drug (56.4%), followed by olanzapine 
(29.6%) and quetiapine (13.9%).1 A common, off-label use of these drugs in older adults 
has been the management of behavioural symptoms in dementia. In the U.S., none of the 
atypical antipsychotic drugs have been approved for the management of behavioural 
symptoms.3 In Canada, risperidone has been the only atypical antipsychotic drug 
approved for the particular purpose.4 The annual incidence of antipsychotic drug 
prescription among older patients with dementia has risen 20% in Ontario, from 1,512 
prescriptions per 100,000 patients in 2002 to 1,813 prescriptions per 100,000 patients in 
2007.2 
 
2.4 Factors associated with atypical antipsychotic drug use 
in older adults 
A number of demographic factors and comorbid conditions have been associated with 
atypical antipsychotic drug use. 
2.4.1 Age 
Previous studies of older adults have suggested patients with more advanced age are less 
likely to use atypical antipsychotic drugs.80,81 A cross-sectional study of older British 
adults found progressive reduction in the odds of using antipsychotic drugs with respect 
to increasing age.80 Adults aged between 75 and 84 years were significantly less likely to 
use antipsychotic drugs compared patients aged between 65 and 74 years (OR 0.61 [95% 
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CI 0.47–0.79]; P < 0.05).80 In the same study, older adults aged 85 years and older also 
had significantly lower odds of using the drugs compared to adults aged between 65 and 
74 years (OR 0.36 [95% CI 0.27–0.46]; P < 0.05).80 Kamble et al.81 found similar 
associations between age and antipsychotic drug use in their cross-sectional survey of 
U.S. long-term care residents. When compared to residents aged between 65 and 74 
years, those aged between 75 and 84 years did not have a significantly lower odds of 
using the drugs (OR 0.93 [95% CI 0.77–1.13] P > 0.05).81 However, residents aged 85 
years and older were significantly less likely to use antipsychotic drugs compared to 
those aged between 65 and 74 years (OR 0.70 [95% CI 0.58–0.84]; P < 0.05).81 
2.4.2 Sex 
Previous studies of older adults showed that women were less likely to use atypical 
antipsychotic drugs than men.81,82 For example, a cross-sectional study conducted in 
long-term care facilities showed that female residents were significantly less likely to use 
antipsychotic drugs compared to male residents (OR 0.80 [95% CI 0.70–0.93]; P < 
0.05).81 Similarly, Bronskill et al.82 demonstrated that older women had a lower odds of 
receiving antipsychotic drugs compared to older men (OR 0.69 [95% CI 0.64–0.75]) 
from the analysis of 19,870 long-term care residents in Ontario. 
2.4.3 Residential status 
Healthcare use by older adults who reside in long-term care facilities could differ 
compared to those dwelling in communities.83,84 Lindesay et al.80 conducted a cross-
sectional survey of adults aged 65 years and older in the U.K. and found older adults 
living in nursing homes were significantly more likely to use antipsychotic drugs 
compared to those living in residential or voluntary homes (OR 1.97 [95% CI 1.52–2.55]; 
P < 0.05). Another cross-sectional study found similar results among older Swedish 
adults.85 In the study, older adults living in long-term care facilities had an increased odds 
of using antipsychotic drugs compared to those not living in such facilities (OR 2.72 
[95% CI 1.29–5.74]).85 
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2.4.4 Dementia and mental disorders 
Quetiapine, risperidone, and olanzapine have been indicated for the treatment of 
schizophrenia and bipolar disorder.74 Kamble et al.81 found long-term care residents with 
schizophrenia had a significantly higher odds of using antipsychotic drugs than residents 
without schizophrenia (OR 11.15 [95% CI 7.84–15.87]; P < 0.05). Moreover, they also 
showed that residents with bipolar disorder were significantly more likely to use the 
drugs compared to residents without the disorder (OR 3.97 [95% CI 2.52–6.24]; P < 
0.05).81 
Although risperidone has been the only atypical antipsychotic drug approved for the use 
of managing behavioural symptoms of dementia in Canada, quetiapine and olanzapine 
have also been widely used for this purpose.2,4 A retrospective cohort study conducted in 
Ontario’s long-term care facilities found older patients with a history of dementia were 
more likely to receive antipsychotic drugs compared to those without such a history (OR 
3.52 [95% CI 3.24–3.82]).82 Similarly, in the U.S., long-term care residents diagnosed 
with dementia were also significantly more likely to use antipsychotic drugs than 
residents without such a diagnosis (OR 2.23 [95% CI 1.94–2.57]; P < 0.05).81 Also in 
Finland, a cross-sectional analysis of 1,987 long-term care residents showed that atypical 
antipsychotic drug use was more common among patients with dementia than those 
without dementia (28.3% versus 24.2%; P = 0.062).86 
In addition to the treatment of patients with schizophrenia, bipolar disorder, or dementia, 
atypical antipsychotic drugs have also been used as an adjunctive treatment of major 
depression and anxiety disorders.87–92 A cross-sectional survey of long-term care facilities 
in the U.S showed that patients with anxiety disorder were significantly more likely to 
use the antipsychotic drugs than those without such disorder (OR 1.70 [95% CI 1.43–
2.00]; P < 0.05).81 In the same study, patients who had depression also had a significantly 
increased odds of using antipsychotic drugs compared to those who did not have 
depression (OR 1.18 [95% CI 1.04–1.33]; P < 0.05).81 Moreover, a British cross-
sectional survey demonstrated that patients who used antidepressant drugs were 
significantly more likely to also use antipsychotic drugs compared to those who did not 
use antidepressant drugs. (OR 1.42 [95% CI 1.16–1.74]; P < 0.05).80 
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2.5 Atypical antipsychotic drugs and potential reasons for 
AKI 
Potential reasons for AKI from atypical antipsychotic drug use include hypotension, 
acute urinary retention, neuroleptic malignant syndrome/rhabdomyolysis, and acute 
cardiac events (see Figure 1). 
2.5.1 Hypotension 
Hypotension (an abnormally low blood pressure) is a well-known cause of AKI, where 
decreased renal perfusion leads to reduction in kidney function and when prolonged, 
results in intrinsic damage to the kidneys.33,59 The ability of atypical antipsychotic drugs 
to block alpha-adrenergic receptors has been postulated to result in vasodilation and a 
subsequent reduction in blood pressure.78,93 Orthostatic hypotension is a type of 
hypotension where systolic blood pressure decreases by at least 20 mmHg and/or 
diastolic blood pressure declines by at least 10mmHg while transitioning from a lying to 
standing position.94 Previous chart reviews of older patients have attributed orthostatic 
hypotension to atypical antipsychotic drug use.95–97 For example, a chart review of 189 
older patients with orthostatic hypotension attributed 5 (2.6%) cases to quetiapine use, 15 
(7.9%) cases to risperidone use, and 4 (2.1%) cases to olanzapine use.95 
Hypotension is a common adverse drug reaction observed in clinical trials of atypical 
antipsychotic drugs in older adults.13–18 Sajatovic et al.13 performed an analysis of data 
pooled from two randomized placebo-controlled trials (12 weeks in duration) that 
included adults aged 55 years and older with bipolar disorder. Their analysis found 
orthostatic hypotension in 5 out of 28 (17.9%) patients treated with quetiapine versus 1 
out of 31 (3.2%) patients in the placebo group.13 Moreover, one patient treated with 
quetiapine suffered unspecified kidney failure and died.13 In an open-label, single-arm 
trial (13 months in duration) of quetiapine that included 184 older patients with 
psychosis, 28 (15.2%) patients experienced orthostatic hypotension and 32 (17.4%) 
patient experienced dizziness.14 The median time to onset for orthostatic hypotension and 
dizziness was 18 and 15 days, respectively.14 In another open-label, single arm trial of 
quetiapine involving 100 geriatric inpatients (4 weeks in duration), 9 (9.0%) patients 
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suffered orthostatic hypotension and 27 (27.0%) patients experienced dizziness.15 A 
randomized, open-label trial (6 months in duration) allocated 27 patients to risperidone 
treatment and 34 patients to olanzapine treatment.17 In the risperidone group, 3 (11.1%) 
patients developed orthostatic hypotension and 5 (18.5%) patients had unspecified renal 
adverse events.17 In the olanzapine group, orthostatic hypotension occurred in 4 (11.8%) 
patients.17 In a 12-week long open-label, single-arm study of risperidone that included 
103 older patients with psychosis, orthostatic hypotension and dizziness were observed in 
5 patients (4.9%) and 23 (22.3%) patients, respectively.16 In another open-label, single-
arm trial of risperidone, which followed 110 older patients with psychosis for four weeks, 
6 (5.5%) patients developed orthostatic hypotension and 32 (29.1%) patients experienced 
dizziness.18  
2.5.2 Acute urinary retention 
Acute urinary retention is an abrupt inability to empty the bladder and this can cause 
AKI.59,98 Muscarinic acetylcholine receptors are present in the urinary tract and are 
involved in the biological pathways of micturition.8,98,99 Atypical antipsychotic drugs 
have anticholinergic properties and thus, it has been postulated in some cases that the 
drugs antagonize muscarinic acetylcholine receptors leading to acute urinary retention.8 
Acute urinary retention has been attributed to the use of quetiapine, risperidone, or 
olanzapine in case reports.8,20,21 In the report of two older patients who developed acute 
urinary retention after olanzapine use, both suffered AKI.8 
2.5.3 Neuroleptic malignant syndrome and rhabdomyolysis 
Neuroleptic malignant syndrome is a serious adverse drug reaction that can occur from 
antipsychotic drugs. Neuroleptic malignant syndrome is characterized by altered mental 
status, autonomic dysfunction, extrapyramidal side effects, high fever, and elevated 
serum creatine kinase level.100 Elevated creatine kinase level is a biomarker for muscle 
damage and may also indicate rhabdomyolysis.69 Although the biological mechanism is 
not entirely clear, the sudden blockade of dopamine receptors by atypical antipsychotic 
drugs has been postulated to result in neuroleptic malignant syndrome.22,30 It has been 
also hypothesized that, since dopaminergic neurons regulate the sympathetic nervous 
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system, the down-regulation of their activity by atypical antipsychotic drugs can lead to 
hyperactivity of the sympathetic nervous system and subsequent muscle damage.25,26,101  
Previous chart reviews of approximately 100 patients hospitalized with rhabdomyolysis 
attributed 5.5 to 7.5% of the cases to quetiapine use.23,24 A retrospective review of 
patients hospitalized with olanzapine overdose showed a correlation between the quantity 
of ingested olanzapine and the proportion of patients with creatine kinase level greater 
than 500 IU/L (Pearson’s r = 0.91).102 Individual cases of rhabdomyolysis have also been 
reported from the use of risperidone or olanzapine at therapeutic dosages and from the 
use of quetiapine at therapeutic dosages and due to overdose.9–12,25–29,103,104 A common 
complication of rhabdomyolysis is AKI, occurring in 15 to 46% of patients who suffer 
the muscle breakdown (by mechanisms described in Section 2.2.7).73,105 Several case 
reports have attributed AKI to the use of quetiapine, risperidone, or olanzapine where the 
kidney injury was mediated by neuroleptic malignant syndrome and/or rhabdomyolysis.9–
12 Another case report described the development of AKI following rhabdomyolysis 
induced by quetiapine overdose.103 
2.5.4 Acute cardiac events 
Acute cardiac events can result in hemodynamic instability and AKI may precipitate from 
such events due to decreased renal perfusion.33,59 In a retrospective cohort study of 
147,007 patients hospitalized with acute myocardial infarction, 28,545 (19.4%) of the 
patients developed AKI.106 Pariente et al.31 conducted a retrospective cohort study in 
Quebec to compare the risk of acute myocardial infarction between older patients with 
dementia who were initiated on antipsychotic drug therapy and those were not initiated 
on such a therapy. Among 10,969 antipsychotic drug users studied, 97.8% were initiated 
on atypical antipsychotic drugs and the drug use versus non-use was associated with a 30-
day higher risk of acute myocardial infarction (HR 2.19 [95% CI 1.11–4.32]).31 
In addition to acute myocardial infarction, ventricular arrhythmias have also been 
attributed to atypical antipsychotic drug use.32 QT interval prolongation is a cardiac 
condition that can lead to ventricular arrhythmia and sudden cardiac death.107 Atypical 
antipsychotic drugs can induce QT interval prolongation by antagonizing cardiac 
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potassium ion channels and thereby delaying repolarization of the heart.108 Individual 
cases of QT interval prolongation have been attributed to quetiapine or risperidone use at 
both therapeutic dosages and due to overdose.109–115 Ray et al.32 conducted a retrospective 
cohort study of 279,900 U.S adults (mean age 46 years) to examine the relationship 
between antipsychotic drug use and sudden cardiac death. In this study, antipsychotic 
drug use versus non-use was associated with a significantly greater risk of sudden cardiac 
death (rate ratio 2.26 [95% CI 1.88–2.72]; P < 0.001).32 There was a dose-dependent 
relationship between the dose of antipsychotic drug used and the incidence of sudden 
cardiac death, supporting a causal relationship between the drug use and sudden cardiac 
death.32 The elevated risk of sudden cardiac death was consistently found in subgroups of 
quetiapine users (rate ratio 1.88 [95% CI 1.30–2.71]), risperidone users (rate ratio 2.91 
[95% CI 2.26–3.76]), and olanzapine users (rate ratio 2.04 [95% CI 1.52–2.74]).32 
2.6 Atypical antipsychotic drugs and the risk of death in 
older adults 
In 2005, the U.S. Food and Drug Administration issued a boxed warning regarding the 
increased mortality associated with atypical antipsychotic drug use in older patients with 
dementia.3 A boxed warning is an alert that is present on the prescribing information of a 
medication. The black box warning was based on the analyses of 17 placebo-controlled 
trials (averaging about 10 weeks in duration), which demonstrated approximately 1.6 to 
1.7-fold increase in mortality rate in older patients with dementia treated with atypical 
antipsychotic drugs compared to patients in the placebo group.3 The incidence of death 
was 4.5% in patients treated with atypical antipsychotic drugs versus 2.6% in the placebo 
group.3 Later in the same year, Health Canada announced a similar warning, advising 
healthcare professionals of the increased mortality associated with atypical antipsychotic 
drug treatment.4 Health Canada’s advisory was based on 13 randomized placebo-
controlled trials that showed approximately 1.6-fold increase in mortality rate in older 
patients with dementia treated with atypical antipsychotic drugs compared to patients in 
the placebo group.4 Subsequently, a meta-analysis of 15 randomized placebo-controlled 
trials (10 to 12 weeks in duration) comparing atypical antipsychotic drug treatment with 
placebo in older patients with dementia also showed supporting evidence for the 
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warning.116 The meta-analysis showed that older patients treated with atypical 
antipsychotic drugs were significantly more likely to die compared to those in the 
placebo group (OR 1.54 [95% CI 1.06–2.23]; P < 0.01).116 
Several population-based observational studies have also examined the risk of death 
associated with atypical antipsychotic drug use in older adults.83,84,117 Gill et al.83 
conducted a retrospective cohort study of older patients with dementia in Ontario to 
characterize the association between newly initiated atypical antipsychotic drug use and 
30-day mortality at the population-level. Their study found atypical antipsychotic drug 
use versus non-use was associated with a higher risk of death in older patients with 
dementia dwelling in communities (HR 1.31 [95% CI 1.02–1.70]).83 A similar 
association between the drug use and mortality was found in older patients with dementia 
residing in long-term care facilities (HR 1.55 [95% CI 1.15–2.07]).83 A subsequent 
retrospective cohort study investigated the 30-day risk of serious events (defined as 
events that required hospitalization or resulted in death) associated with newly 
commenced atypical antipsychotic drug use in older patients with dementia.84 This study 
found atypical antipsychotic drug use versus non-use was associated with an increased 
odds of serious events in older patients with dementia dwelling in communities (OR 3.19 
[95% CI 2.77–3.68]).84 A similar association between the drug use and serious events 
was found in older patients with dementia residing in long-term care facilities (OR 1.92 
[95% CI: 1.68–2.21]).84 In the U.S., Huybrechts et al.117 conducted a retrospective cohort 
study to compare the risk of death among older long-term care residents newly initiated 
on different atypical antipsychotic drugs.117 The mortality rate was 28.4 deaths per 100 
person-years among quetiapine users, 36.2 deaths per 100 person-years among 
risperidone users, and 36.7 deaths per 100 person-years among olanzapine users within 
180 days after initiation of respective atypical antipsychotic drug treatment.117 This study 
found a lower risk of death in quetiapine users compared to risperidone users (HR 0.80 
[95% CI 0.74–0.86]).117 The risk of death in olanzapine users was not statistically 
different from that of risperidone users (HR 1.01 [95% CI 0.95–1.07]).117 
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Figure 1: Putative biological mechanisms by which atypical antipsychotic drug use may 
lead to AKI 
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Chapter 3  
3 Rationale and Research Questions 
 
3.1 The need for research 
Adverse drug reactions occur frequently among older adults with an incidence rate of 
50.1 events per 1000 person-years.118 Approximately 28% of the adverse drug reactions 
are preventable and kidney-related adverse events account for 27% of the preventable 
adverse events.118,119 There currently exist genuine concerns about the safety of atypical 
antipsychotic drug use in older adults. For example, this class of drugs is commonly and 
increasingly being used for the unapproved indication of managing behavioural 
symptoms of dementia despite the federal warnings that advise of the risk of death 
associated with the drug treatment.2–4 Determining the risk of AKI associated with 
atypical antipsychotic drug use will contribute to emerging knowledge regarding the 
safety of their use in older adults. There exist several case reports attributing AKI to 
atypical antipsychotic drug use, along with potential reasons why AKI may occur in this 
setting.8–32 However, the association between atypical antipsychotic drug use and AKI 
has not been characterized in previous clinical or epidemiologic investigations. 
Therefore, we aimed to characterize the risk of hospitalization with AKI associated with 
new atypical antipsychotic drug use versus non-use. Additionally, we intended to identify 
potential reasons for AKI in this setting. 
 
3.2 Research questions and hypotheses 
3.2.1 Primary research question 
Compared to non-use, is new atypical antipsychotic drug use associated with a higher risk 
of hospitalization with AKI in older adults? 
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Hypothesis: We hypothesize that, compared to non-use, new atypical antipsychotic drug 
use is associated with a higher risk of hospitalization with AKI in older adults. 
3.2.2 Secondary research questions 
1) Compared to non-use, is new atypical antipsychotic drug use associated with a higher 
risk of hospitalization with conditions that can be responsible for AKI in older adults? 
These five conditions are: hypotension, acute urinary retention, neuroleptic malignant 
syndrome/rhabdomyolysis, acute myocardial infarction, and ventricular arrhythmia. 
Each of these conditions will be examined separately as a secondary outcome. 
Hypothesis: We hypothesize that, compared to non-use, new atypical antipsychotic 
drug use is associated with a higher risk of hospitalization with each of the conditions 
that can be responsible for AKI in older adults. 
2) Compared to non-use, is new atypical antipsychotic drug use associated with a higher 
risk of all-cause mortality in older adults? 
Hypothesis: We hypothesize that, compared to non-use, new atypical antipsychotic 
drug use is associated with a higher risk of all-cause mortality in older adults. 
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Chapter 4  
4 Methods 
 
4.1 Study design and setting 
We conducted a population-based retrospective matched cohort study of older adults 
using linked healthcare administrative databases in Ontario. Approximately 1.8 million 
adults aged 65 years and older reside in Ontario.120 Older residents of Ontario have 
comprehensive, universal healthcare that covers outpatient drug prescriptions, physician 
services, and hospitalizations under a single-payer healthcare system. 
We conducted this study according to a pre-specified protocol that was approved by the 
research ethics board at Sunnybrook Health Sciences Centre in Toronto, Ontario. The 
reporting of this study followed the Strengthening the Reporting of Observational Studies 
in Epidemiology (STROBE) guidelines (see Appendix A for checklist).121 
 
4.2 Data sources 
We used following six healthcare administrative databases housed at the Institute for 
Clinical Evaluative Sciences to ascertain drug exposure, covariate information, and 
outcome data: 
1) Ontario Drug Benefit (ODB) Database 
The ODB database stores records of all outpatient drug prescriptions dispensed to 
patients aged 65 years and older in Ontario with a high level of accuracy (overall 
error rate of less than 1%).122 We used this database to ascertain exposure to atypical 
antipsychotic drugs and baseline medication use. We also acquired information on 
patient residential status (community-dwelling or long-term care) and medical 
specialty of the physicians who prescribed atypical antipsychotic drugs. 
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2) Ontario’s Registered Persons Database (RPDB) 
We used RPDB to attain information on patient demographics (age, sex, and vital 
status), income (categorized into quintiles of average neighbourhood income), and 
location of residence (urban or rural). Moreover, we used the vital status information 
captured by this database to ascertain the outcome of all-cause mortality. 
3) Canadian Institute for Health Information Discharge Abstract Database (CIHI-DAD) 
CIHI-DAD contains diagnostic and procedural information on all hospitalizations 
occurred in Ontario. A maximum of 25 unique diagnosis codes (for example, codes 
for AKI, hypotension, or acute urinary retention) can be assigned to each 
hospitalization. The hospital diagnosis codes were based on the International 
Classification of Diseases, Ninth Revision (ICD-9) codes prior to 2002 and ICD-10 
codes since 2002. We used both ICD-9 and ICD-10 codes to determine baseline 
comorbid conditions (detailed in Appendix B). We used ICD-10 codes exclusively to 
determine hospitalized outcomes as the cohort entry of the patients commenced in 
2003 (detailed in Appendix C). 
4) Ontario Health Insurance Plan (OHIP) Database 
The OHIP database stores information on physician claims on inpatient and 
outpatient services using fee codes. We used the information captured by the database 
to identify baseline comorbid conditions in addition to the diagnostic information 
attained from CIHI-DAD. 
5) Ontario Mental Health Reporting System (OMHRS) Database 
The OMHRS database contains demographic and health information on patients 
admitted to adult mental health beds in Ontario. The diagnosis codes used record 
health conditions in this database were based on the Diagnostic and Statistical Manual 
of Mental Disorders, 4th Edition (detailed in Appendix B). In addition to CIHI-DAD 
and OHIP database, we used the diagnostic information stored in this database to 
determine baseline psychiatric comorbid conditions. 
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6) Cerner and Gamma-Dynacare Laboratory Databases 
A subpopulation of patients in Southwestern Ontario had outpatient serum creatinine 
and urine dipstick protein measurements available before cohort entry and was in the 
catchment area of 12 hospitals in which linked serum creatinine laboratory 
measurements were available through these laboratory datasets.123 We used the 
information to assess baseline kidney function and to ascertain the outcome of AKI 
defined using serum creatinine values. 
All six databases have been repeatedly used to study health outcomes including adverse 
drug reactions in previous studies.83,84,124–128 
 
4.3 Patients 
We accrued all adults aged 66 years and older in Ontario who were dispensed a new oral 
outpatient prescription for an atypical antipsychotic drug (quetiapine, risperidone, or 
olanzapine) between June 2003 and December 2011 to the drug user group. The date of 
this prescription served as the ‘index date’ for the drug users. We then randomly assigned 
an index date to all Ontario residents 66 years and older who were not dispensed a 
prescription for any antipsychotic drug (according to the index date of the drug users) and 
accrued them to the non-user group. For example, if more drug users were accrued 
between 2005 and 2006, a larger proportion of nonusers would be randomly assigned an 
index date between 2005 and 2006. We excluded the following patients from both 
groups: (1) those with prescriptions for any antipsychotic drug in the 180 days prior to 
their index date to ensure the drug users were newly prescribed, (2) those who were 
discharged from a hospital in the two days before their index date to ensure the drug users 
were newly initiated on an atypical antipsychotic drug in an outpatient setting and the 
non-users had the potential to be newly initiated on such a drug in an outpatient setting, 
and (3) those with an evidence of end-stage kidney disease (since the development of 
AKI is no longer relevant). From the drug user group, we excluded individuals who 
received a prescription for more than one type of antipsychotic drug on their index date to 
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compare mutually exclusive groups in subgroup analysis. From the non-user group, we 
excluded individuals without any outpatient medication dispensed in the 90 days prior to 
their index date to ensure that the non-users could have been prescribed a drug in Ontario. 
 
4.4 Matching 
The Consolidated Standards of Reporting Trials statement defined selection bias as a 
“systematic error in creating intervention groups, causing them to differ with respect to 
prognosis. That is, the groups differ in measured or unmeasured baseline characteristics 
because of the way in which participants are selected for the study or assigned to their 
study groups.”129 In randomized controlled trials, random allocation of treatment reduces 
selection bias as the method, on average, distributes both measured and unmeasured 
baseline factors similarly to the groups being compared.130,131 However, in cohort studies, 
the exposure status is not randomly determined and thus, the exposed and unexposed 
groups can differ in baseline characteristics that may affect the outcome.131 
Consequently, cohort studies are susceptible to selection bias and this form of bias can 
lead to confounding.131,132 Koepsell and Weiss133  stated “confounding occurs in 
epidemiologic research when the measured association between an exposure and disease 
occurrence is distorted by an imbalance between exposed and non-exposed persons in 
regard to one or more other risk factors for the disease.” Matching is a method used to 
reduce selection bias by forming exposed and unexposed groups that are similar with 
respect to baseline characteristics that may affect the outcome.134 Therefore, we used the 
method of matching to minimize selection bias and to control for potential confounding.  
Propensity score matching allowed us to form a matched set of patients in the drug user 
and non-user groups with similar probability of receiving an atypical antipsychotic drug 
(the propensity score) conditional on observed baseline covariates.135,136 Following the 
guidance provided by recent methodological studies, we incorporated the following three 
types of variables into the propensity score136–138: (1) variables that are associated with 
atypical antipsychotic drug use, (2) risk factors for AKI, and (3) variables that are 
associated with both atypical antipsychotic drug use and AKI. We estimated the 
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propensity score using a multivariable logistic regression model that included following 
27 covariates: age (per year); sex (men or women); year of cohort entry (2003, 2004, 
2005, 2006, 2007, 2008, 2009, 2010, or 2011); residential status (community-dwelling or 
long-term care); evidence of dementia (yes or no), schizophrenia or other psychotic 
disorder (yes or no), bipolar disorder (yes or no), major depression and/or anxiety 
disorder (yes or no), chronic kidney disease (yes or no), cerebrovascular disease (yes or 
no), chronic liver disease (yes or no), congestive heart failure (yes or no), coronary artery 
disease (yes or no), diabetes mellitus (yes or no), hypertension (yes or no), and peripheral 
vascular disease (yes or no); the use of anticonvulsant (yes or no), antidepressant (yes or 
no), cholinesterase inhibitor (yes or no), lithium (yes or no), ACE inhibitor or ARB (yes 
or no), beta-adrenergic antagonist (yes or no), calcium channel blocker (yes or no), 
NSAID excluding aspirin (yes or no), potassium sparing diuretic (yes or no), non-
potassium sparing diuretic (yes or no), and statin (yes or no). 
Subsequently, we matched a non-user to each drug user on the following 12 
characteristics: the logit of the propensity score (within caliper of ± 0.2 standard 
deviations139); age (within two years); sex; index date (within six months); residential 
status (community-dwelling or long-term care); evidence of dementia (yes or no), 
schizophrenia or other psychotic disorder (yes or no), bipolar disorder (yes or no), major 
depression and/or anxiety disorder (yes or no), CKD (yes or no); a recently dispensed 
medication from a pharmacy in the catchment area of linked hospital-based laboratory 
measurements (yes or no)123; availability of serum creatinine measurement in the year 
prior to the index date (yes or no). We matched the patients without replacement and 
using greedy matching technique. Patients who were not matched successfully were 
excluded from our analysis. Previously, it has been shown that optimal matching does not 
perform better than greedy matching in forming balanced groups.140 Greedy matching 
was preferred over optimal matching for the purpose of computing efficiency. 
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4.5 Baseline characteristics 
We assessed baseline comorbid conditions in the five years prior to the index date and 
medication use in the 180 days prior to the index date of each atypical antipsychotic drug 
user and non-user (see Appendix B for coding information). For the subpopulation of 
patients whose laboratory measurements were available, we assessed their kidney 
function in the year prior to their index date. 
 
4.6 Outcomes 
We followed patients for 90 days after the index date to assess the pre-specified 
outcomes. We elected for the 90-day follow-up period to (1) focus on short-term adverse 
outcomes, (2) avoid potential crossovers among different types of atypical antipsychotic 
drugs that may occur with longer periods of follow-up, and (3) mimic the duration of 
follow-up where safety outcomes were reported in clinical trials of atypical antipsychotic 
drug treatment in older adults.3,4,116 The primary outcome was hospitalization with AKI. 
The secondary outcomes were potential reasons for AKI (hospitalization with 
hypotension, hospitalization with acute urinary retention, hospitalization with neuroleptic 
malignant syndrome/rhabdomyolysis, hospitalization with acute myocardial infarction, 
and hospitalization with ventricular arrhythmia), and all-cause mortality. Hospital 
diagnosis codes used to ascertain the outcomes are presented in Appendix C. Because up 
to 25 diagnosis codes can be assigned per hospitalization, patients with codes for several 
study outcomes were accounted under each outcome present. 
In our validation study, the hospital diagnosis code for AKI in Ontario identified a 
median (interquartile range) absolute increase in serum creatinine of 98 µmol/L (43 to 
200 µmol/L) from the most recent measured value prior to hospitalization, whereas its 
absence identified a median (interquartile range) increase of 6 µmol/L (IQR −4 to 20 
µmol/L).141 Patients hospitalized with AKI might or might not have the hospital diagnosis 
code recorded. The code was more likely to be present for patients with more severe 
forms of AKI, indicated by larger increases in serum creatinine.141 When compared 
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against the reference standard of increases in serum creatinine, the specificity of the code 
was greater than 95%.141 However, the sensitivity of the code ranged from 22 to 66% 
with the metric being lower for milder forms of AKI and thus, the code underestimated 
the true incidence of AKI.141 Therefore, in the subpopulation of patients whose serum 
creatinine measurements were available, we examined AKI defined as an absolute 
increase in serum creatinine concentration of 27 μmol/L or greater or a relative increase 
by 50% or more from the most recently measured serum creatinine concentration in the 
year prior to the patient’s index date (on the basis of the Acute Kidney Injury Network 
staging system).35 
The known validity of hospital diagnosis codes for secondary outcomes is presented in 
Appendix C. Using reabstracted information written in a patient’s chart as the reference 
standard, the hospital diagnosis code for hypotension and acute urinary retention had a 
sensitivity of 72% and 86% and positive predictive value of 39% and 48%, each 
respectively.142 Using the same reference standard, one of the two codes for acute 
myocardial infarction had a sensitivity of 89% and positive predictive value of 87%.142 
The codes for neuroleptic malignant syndrome/rhabdomyolysis and ventricular 
arrhythmia have not been validated in our region and are not expected to be sensitive. 
However, there was no reason to suspect differential misclassification of these diagnosis 
codes between atypical antipsychotic drug users and non-users. Another secondary 
outcome was all-cause mortality and the corresponding code has been found to be highly 
accurate for identifying death with a sensitivity of 94% and specificity of 100%.143 
We considered examining the robustness of our findings using tracer outcomes (also 
referred to as falsification end-points).144,145 Tracer outcomes are those outcomes that are 
hypothesized to be causally unrelated to the exposure; the presence of an association 
between the exposure and tracer outcome would suggest that the observed associations in 
the study may be confounded.144 However, after detailed review, we elected against this 
given the wide range of adverse effects reported with atypical antipsychotic drugs.  
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4.7 Statistical analyses 
We compared baseline characteristics between atypical antipsychotic drug users and non-
users using standardized differences. This metric describes differences between group 
means with respect to pooled standard deviation and indicates a meaningful difference if 
greater than 0.10 (10%).136,146,147 The use of standardized differences has been 
recommended over that of statistical hypothesis testing (using P values) for assessing 
balance in baseline characteristics between propensity score matched groups.148–150 The 
standardized difference is not influenced by sample size and thus, one can compare the 
balance in the unmatched sample to that in the matched sample.149,150 
We measured the risk for the primary and secondary outcomes in both absolute and 
relative terms. We calculated absolute risk differences and 95% CIs using a method that 
accounts for matching.151 Absolute risk difference was further expressed as the number 
needed to harm (NNH; 1/absolute risk difference), a measure that indicates how many 
patients need to receive an atypical antipsychotic drug to cause harm to one patient who 
otherwise would not have been harmed. NNH was calculated for ease of interpretation 
and not to imply causality. We used conditional logistic regression to estimate ORs and 
95% CIs for the primary and secondary outcomes by using the non-user group as the 
referent group. 
We repeated the analysis of the primary outcome (hospitalization with AKI) in four pre-
specified subgroups: (1) evidence of CKD (present or absent), (2) antipsychotic drug type 
(quetiapine, risperidone, or olanzapine), (3) antipsychotic drug dose (high dose or low 
dose; high dose defined by a higher than median daily dose for the matched cohort 
[quetiapine >25 mg/day, risperidone >0.5 mg/day, and olanzapine >2.5 mg/day]), and (4) 
residential status (community-dwelling or long-term care). Each matched set of the drug 
users and non-users were included in subgroups defined by the antipsychotic drug type 
and dose based on the characteristics of the drug users. 
CKD was identified using an algorithm of hospital diagnosis codes validated in our 
region for older adults.152 The algorithm identified patients with a median (interquartile 
range) estimated GFR of 38 mL/min/1.73 m2 (27 to 52 mL/min/1.73 m2), whereas its 
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absence identified patients with a median (interquartile range) estimated GFR of 69 
mL/min/1.73 m2 (56 to 82 mL/min/1.73 m2).152 The algorithm for CKD had a sensitivity 
of 32% and specificity of 94% using an estimated GFR of 45 mL/min/1.73 m2 as the 
referent standard.152 Due to its limited sensitivity, the algorithm underestimated the true 
prevalence of CKD.152 
All ORs were interpreted as RRs, which was appropriate given the observed incidence of 
the study outcomes (less than 10%). We performed all analyses using SAS version 9.2 
(SAS Institute, Cary, North Carolina, USA, 2008). 
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Chapter 5  
5 Results 
 
5.1 Cohort characteristics 
5.1.1 Unmatched cohort 
Cohort selection is presented in Figure 2 and baseline characteristics of the unmatched 
and matched cohorts are presented in Table 1. Prior to matching, we identified 122,610 
atypical antipsychotic drug users and 1,204,613 non-users. The drug users were older 
than the non-users and were more likely to be female and reside in long-term care 
facilities. The users were more likely to be diagnosed with dementia, schizophrenia or 
other psychotic disorder, bipolar disorder, major depression and/or anxiety disorder, 
chronic kidney disease, cerebrovascular disease, congestive heart failure, and coronary 
artery disease compared to the non-users. Moreover, the drug users were more likely to 
use anticonvulsants, antidepressants, cholinesterase inhibitors, and lithium. The drug 
users were less likely to use ACE inhibitors or ARBs and statins compared to the non-
users (Table 1). Information on income was not available for 676 (0.6%) drug users and 
4,380 (0.4%) non-users. Location of residence could not be ascertained for 234 (0.2%) 
drug users and 1,142 (0.1%) non-users. 
5.1.2 Matched cohort 
After matching, 96,471 pairs of atypical antipsychotic drug users and non-users remained 
in the cohort. The two groups were well balanced showing no meaningful difference in 
the 29 baseline characteristics measured: age, sex, income, year of cohort entry, location 
of residence, residential status, 12 comorbid conditions, and use of 11 medications (Table 
1). The mean age was 81 years, 64.6% of patients were women and 23.9% resided in 
long-term care facilities. More than half of patients (53.9%) had a diagnosis of dementia. 
7.6% of patients were diagnosed with schizophrenia or other psychotic disorder and 4.9% 
was diagnosed with bipolar disorder. A diagnosis of major depression and/or anxiety 
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disorder was made on 18.9% of patients. The most frequently prescribed atypical 
antipsychotic drug was risperidone (45.3%), followed by quetiapine (35.9%) and 
olanzapine (18.8%). The median (interquartile range) daily dose for quetiapine was 25 
(25–50) mg/day, for risperidone was 0.5 (0.3–0.6) mg/day, and for olanzapine was 2.5 
(2.5–5.0) mg/day. The prescriber information was not available for 10.7% of the atypical 
antipsychotic drug users. When the prescriber information was available (89.3% of the 
drug users), general practitioners (82.0%) were the most frequent prescribers of atypical 
antipsychotic drugs, followed by psychiatrists (7.1%) and geriatricians (4.7%). Income 
could not be ascertained for 448 (0.5%) drug users and 386 (0.4%) non-users. Location of 
residence could not be identified for 177 (0.2%) drug users and 109 (0.1%) non-users. 
Baseline characteristics of patients from the subpopulation in Southwestern Ontario with 
available serum creatinine measurements are presented in Table 2. Within the matched 
cohort, there were 1,442 pairs of atypical antipsychotic drug users and non-users were 
from the subpopulation. The two groups were well balanced showing no meaningful 
differences in the 29 baseline characteristics including age, sex, income, year of cohort 
entry, location of residence (urban or rural), residential status (community-dwelling or 
long-term care), 10 comorbid conditions, use of 10 medications, baseline serum 
creatinine concentration, estimated GFR, and urine dipstick protein (Table 2). However, 
the drug users were more likely to have a diagnosis of cerebrovascular disease than the 
non-users (7.0% versus 4.4%; standardized difference = 0.11). The number of patients 
with bipolar disorder, use of lithium, and estimated GFR less than 15 mL/min/1.73m2 
was too few (less than five) and were not reported for reasons of patient privacy.   
 
5.2 Main analysis 
The primary outcome was 90-day hospitalization with AKI, assessed with a hospital 
diagnosis code and with serum creatinine values. The 90-day incidence of hospitalization 
with AKI assessed with a hospital diagnosis code in the atypical antipsychotic drug user 
group was 1.06% (1,022 events) and in the non-user group was 0.52% (500 events). 
Atypical antipsychotic drug use versus non-use was associated with a greater risk of 
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hospitalization with AKI (RR 2.06 [95% CI 1.85–2.29]; absolute risk difference 0.54% 
[95% CI 0.46%–0.62%]; NNH 185 [95% CI 161–216]). In the subpopulation where AKI 
was assessed using serum creatinine values, the 90-day incidence of hospitalization with 
AKI in atypical antipsychotic drug user group was 1.46% (21 events) and in the non-user 
group was 0.55% (8 events). Atypical antipsychotic drug use versus non-use was 
associated with an increased risk of hospitalization with AKI (RR 2.63 [95% CI 1.16–
5.93]; absolute risk difference 0.90% [95% CI 0.17%–1.63%]; NNH 111 [95% CI 61–
585]) (see Section 4.6 for the serum creatinine-based definition of AKI). 
The potential reasons for AKI assessed with hospital diagnosis codes are considered as 
secondary outcomes and are presented in Table 3. Atypical antipsychotic drug use versus 
non-use was associated with a 90-day higher risk of hospitalization with hypotension (RR 
2.16 [95% CI 1.81–2.57]), acute urinary retention (RR 2.15 [95% CI 1.78–2.60]), 
neuroleptic malignant syndrome/rhabdomyolysis (RR 1.44 [95% CI 1.06–1.96]), acute 
myocardial infarction (RR 1.34 [95% CI 1.19–1.51]), and ventricular arrhythmia (RR 
1.72 [95% CI 1.37–2.14]). Another secondary outcome investigated was all-cause 
mortality and is also presented in Table 3. Atypical antipsychotic drug use versus non-use 
was associated with a 90-day higher risk of all-cause mortality (RR 2.68 [95% CI 2.56–
2.81]). 
 
5.3 Subgroup analysis 
The four subgroup analyses performed are presented in Table 4. The presence of CKD 
did not influence the relative association between atypical antipsychotic drug use and 
hospitalization with AKI (Interaction P = 0.15). The absolute risk difference in the 
incidence of hospitalization with AKI between the drug users and non-users was greater 
in patients with CKD (1.82% [95% CI 1.23%–2.41%]) compared to patients without 
CKD (0.44% [95% CI 0.37%–0.52%]). The association between atypical antipsychotic 
drug use and hospitalization with AKI was not modified by antipsychotic drug type 
(Interaction P = 0.13) nor by antipsychotic drug dose (Interaction P = 0.49). The risk of 
hospitalization with AKI associated with atypical antipsychotic drug use versus non-use 
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was higher in community-dwellers (RR 2.37 [95% CI 2.08–2.71]) than in long-term care 
residents (RR 1.53 [95% CI 1.27–1.85]) (Interaction P < 0.001). 
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215,543 Ontario residents 66 years or 
older who were dispensed a new oral 
outpatient prescription for an atypical 
antipsychotic drug (quetiapine, 
risperidone, or olanzapine) between 
June 2003 and December 2011 
 
1,726,930 Ontario residents 66 years or 
older were not dispensed a new oral 
outpatient prescription for any 
antipsychotic drug between June 2003 
and December 2011 
 
92,933 Patients excluded 
from the atypical 
antipsychotic drug user 
group 
 
58,212 Prescriptions for 
any antipsychotic drug in 
the 180 days prior to the 
index date 
28,802 Discharged from a 
hospital in the two days 
prior to the index date 
1,065 Evidence of end-
stage kidney disease 
4,854 A prescription for 
more than one type of 
antipsychotic drug on the 
index date 
26,139 Unmatched 
122,610 Atypical 
antipsychotic drug users 
96,471 Atypical antipsychotic 
drug non-users 
 
96,471 Atypical 
antipsychotic drug users 
1,108,142 Unmatched 
1,204,613 Atypical 
antipsychotic drug non-users 
 
522,317 Patients excluded 
from the atypical 
antipsychotic drug non-user 
group 
 
34,232 Prescriptions for 
any antipsychotic drug in 
the 180 days prior to the 
index date 
13,298 Discharged from a 
hospital in the two days 
before the index date 
6,047 Evidence of end-
stage kidney disease 
468,740 Without at least 
one outpatient medication 
dispensed in the 90 days 
prior to the index date  
Figure 2: Cohort selection 
 
 Table 1: Baseline characteristics of atypical antipsychotic drug users and non-usersa 
 Unmatched Matched 
Users 
(n=122,610) 
Non-Users 
(n=1,204,613) 
Standardized 
Differenceb 
Users 
(n=96,471) 
Non-Users 
(n=96,471) 
Standardized 
Differenceb 
Demographics 
  Age, mean (SD), years 81 (8) 76 (7) 0.74 81 (8) 81 (8) 0.00 
  Women 77,508 (63.2) 687,831 (57.1) 0.12 62,326 (64.6) 62,326 (64.6) 0.00 
Income quintilec 
  1 (low) 27,282 (22.3) 234,967 (19.5) 0.07 21,347 (22.1) 20,704 (21.5) 0.01 
  2 25,465 (20.8) 253,463 (21.0) 0.00 20,189 (20.9) 19,813 (20.5) 0.01 
  3 (middle) 23,838 (19.4) 234,892 (19.5) 0.00 18,866 (19.6) 18,649 (19.3) 0.01 
  4 23,106 (18.8) 235,555 (19.6) 0.02 18,159 (18.8) 18,497 (19.2) 0.01 
  5 (high) 22,243 (18.1) 241,356 (20.0) 0.05 17,462 (18.1) 18,422 (19.1) 0.03 
Year of cohort entry 
  2003–2004 26,712 (21.8) 229,290 (19.0) 0.07 19,561 (20.3) 19,582 (20.3) 0.00 
  2005–2006 29,640 (24.2) 272,475 (22.6) 0.04 22,501 (23.3) 22,523 (23.3) 0.00 
  2007–2008 25,286 (20.6) 251,863 (20.9) 0.01 19,979 (20.7) 19,882 (20.6) 0.00 
  2009–2010 26,795 (21.9) 289,588 (24.0) 0.05 22,281 (23.1) 22,323 (23.1) 0.00 
  2011 14,177 (11.6) 161,397 (13.4) 0.05 12,149 (12.6) 12,161 (12.6) 0.00 
Rural residenced 15,811 (12.9) 172,157 (14.3) 0.04 12,288 (12.7) 13,400 (13.9) 0.04 
Long-term care 37,598 (30.7) 32,457 (2.7) 0.81 23,063 (23.9) 23,063 (23.9) 0.00 
Comorbid conditionse 
  Dementia 73,839 (60.2) 90,115 (7.5) 1.81 51,983 (53.9) 51,983 (53.9) 0.00 
  Schizophrenia or other 
  psychotic disorder 
15,263 (12.4) 14,095 (1.2) 0.79 7,322 (7.6) 7,322 (7.6) 0.00 
  Bipolar disorder 9,673 (7.9) 11,413 (0.9) 0.56 4,769 (4.9) 4,769 (4.9) 0.00 
  Major depression and/or  
  anxiety disorder 27,250 (22.2) 74,960 (6.2) 0.61 18,239 (18.9) 18,239 (18.9) 0.00 
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  Chronic kidney disease 10,341 (8.4) 70,440 (5.8) 0.11 6,819 (7.1) 6,819 (7.1) 0.00 
  Cerebrovascular disease 9,079 (7.4) 28,550 (2.4) 0.30 6,178 (6.4) 6,145 (6.4) 0.00 
  Chronic liver disease 4,020 (3.3) 36,398 (3.0) 0.01 3,080 (3.2) 3,054 (3.2) 0.00 
  Congestive heart failure 24,999 (20.4) 134,486 (11.2) 0.28 18,662 (19.3) 19,641 (20.4) 0.03 
  Coronary artery diseasef 50,601 (41.3) 420,958 (34.9) 0.13 38,976 (40.4) 40,071 (41.5) 0.02 
  Diabetes mellitusg 20,435 (16.7) 208,112 (17.3) 0.02 15,919 (16.5) 16,720 (17.3) 0.02 
  Hypertensionh 84,209 (68.7) 883,364 (73.3) 0.10 66,913 (69.4) 68,829 (71.3) 0.04 
  Peripheral vascular 
  disease 2,587 (2.1) 17,790 (1.5) 0.05 1,888 (2.0) 2,089 (2.2) 0.01 
Medication usei 
  Anticonvulsant 14,457 (11.8) 45,907 (3.8) 0.39 9,606 (10.0) 10,764 (11.2) 0.04 
  Antidepressant 31,278 (25.5) 85,243 (7.1) 0.66 20,481 (21.2) 21,638 (22.4) 0.03 
  Cholinesterase inhibitor 36,347 (29.6) 25,683 (2.1) 1.41 22,457 (23.3) 20,081 (20.8) 0.06 
  Lithium 1,324 (1.1) 1,317 (0.1) 0.22 599 (0.6) 531 (0.6) 0.01 
  ACE inhibitor or ARB 54,674 (44.6) 617,052 (51.2) 0.13 43,908 (45.5) 45,249 (46.9) 0.03 
  Beta-adrenergic  
  antagonist 37,391 (30.5) 365,976 (30.4) 0.00 29,574 (30.7) 30,216 (31.3) 0.01 
  Calcium channel  
  blocker 33,166 (27.0) 344,285 (28.6) 0.03 26,607 (27.6) 27,499 (28.5) 0.02 
  NSAID (excluding 
  aspirin) 20,720 (16.9) 220,395 (18.3) 0.04 16,626 (17.2) 16,587 (17.2) 0.00 
  Potassium sparing 
  diuretic 7,998 (6.5) 69,486 (5.8) 0.03 6,243 (6.5) 6,590 (6.8) 0.01 
  Non-potassium sparing  
  diuretic 41,896 (34.2) 355,874 (29.5) 0.10 32,567 (33.8) 33,832 (35.1) 0.03 
  Statin 41,975 (34.2) 539,520 (44.8) 0.21 34,019 (35.3) 34,523 (35.8) 0.01 
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 Table 1 (continued) 
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; NSAID, Non-steroidal anti-
inflammatory drug; SD, standard deviation 
aData are presented as the number (percentage) of patients, unless otherwise reported. 
bStandardized difference describes differences between group means with respect to pooled standard deviation and indicates a 
meaningful difference if greater than 0.10 (10%).146,147,150 
cIncome was not available for 676 (0.6%) drug users and 4,380 (0.4%)  non-users in the unmatched cohort and 448 (0.5%) drug 
users and 386 (0.4%) non-users in the matched cohort. 
dLocation of residence was not available for 234 (0.2%) drug users and 1,142 (0.1%) non-users in the unmatched cohort and 177 
(0.2%) drug users and 109 (0.1%) non-users in the matched cohort. 
eComorbid conditions in the 5 years preceding the index date were considered. 
fCoronary artery disease includes diagnoses of angina and receipt of coronary artery bypass graft surgery and percutaneous 
coronary intervention. 
gDiabetes mellitus and were defined by use of any diabetic medication in the  6 months preceding the index date. 
hHypertension was defined by use of any antihypertensive medication in the 6 months preceding the index date. 
iMedication use in the 180 days preceding the index date were considered. 
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 Table 2: Baseline characteristics of atypical antipsychotic drug users and non-users in the subpopulation with available serum 
creatinine measurements (Matched)a 
 Users 
(n=1,442) 
Non-Users 
(n=1,442) 
Standardized 
Differenceb 
Demographics 
  Age, mean (SD), years 79 (7) 80 (7) 0.01 
  Women 938 (65.0) 938 (65.0) 0.00 
Income quintilec 
  1 (low) 333 (23.1) 312 (21.6) 0.04 
  2 270 (18.7) 278 (19.3) 0.02 
  3 (middle) 287 (19.9) 279 (19.3) 0.02 
  4 224 (15.5) 235 (16.3) 0.02 
  5 (high) 287 (19.9) 302 (20.9) 0.02 
Year of cohort entry 
  2003–2004 173 (12.0) 176 (12.2) 0.01 
  2005–2006 319 (22.1) 317 (22.0) 0.00 
  2007–2008 315 (21.8) 323 (22.4) 0.01 
  2009–2010 404 (28.0) 400 (27.7) 0.01 
  2011 231 (16.0) 226 (15.7) 0.01 
Rural residenced 163 (11.3) 167 (11.6) 0.01 
Long-term care 177 (12.3) 177 (12.3) 0.00 
Comorbid conditionse 
  Dementia 614 (42.6) 614 (42.6) 0.00 
  Schizophrenia or other psychotic disorder 42 (2.9) 42 (2.9) 0.00 
  Bipolar disorderf … … … 
  Major depression and/or anxiety disorder 286 (19.8) 286 (19.8) 0.00 
  Chronic kidney disease 48 (3.3) 48 (3.3) 0.00 
  Cerebrovascular disease 101 (7.0) 63 (4.4) 0.11 
  Chronic liver disease 62 (4.3) 49 (3.4) 0.05 
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  Congestive heart failure 281 (19.5) 281 (19.5) 0.00 
  Coronary artery diseaseg 559 (38.8) 593 (41.1) 0.05 
  Diabetes mellitush 269 (18.7) 272 (18.9) 0.01 
  Hypertensioni 1,081 (75.0) 1,096 (76.0) 0.02 
  Peripheral vascular disease 23 (1.6) 22 (1.5) 0.01 
Medication usej 
  Anticonvulsant 97 (6.7) 127 (8.8) 0.08 
  Antidepressant 399 (27.7) 413 (28.6) 0.02 
  Cholinesterase inhibitor 254 (17.6) 225 (15.6) 0.05 
  Lithiumf … … … 
  ACE inhibitor or ARB 714 (49.5) 732 (50.8) 0.02 
  Beta-adrenergic antagonist 506 (35.1) 505 (35.0) 0.00 
  Calcium channel blocker 435 (30.2) 422 (29.3) 0.02 
  NSAID (excluding aspirin) 265 (18.4) 246 (17.1) 0.03 
  Potassium sparing diuretic 119 (8.3) 120 (8.3) 0.00 
  Non-potassium sparing diuretic 515 (35.7) 533 (37.0) 0.03 
  Statin 571 (39.6) 585 (40.6) 0.02 
Kidney functionk 
  Baseline serum creatinine concentration,  
  median (IQR), µmol/L 83 (69–103) 82 (68–100) 0.01 
  Estimated GFR, median (IQR), mL/min/1.73m2 l 64 (50–80) 66 (50–79) 0.02 
  Estimated GFR 
    ≥60 mL/min/1.73m2 824 (57.1) 870 (60.3) 0.07 
    45-59 mL/min/1.73m2 346 (24.0) 336 (23.3) 0.02 
    30-44 mL/min/1.73m2 209 (14.5) 179 (12.4) 0.06 
    15-29 mL/min/1.73m2 58 (4.0) 53 (3.7) 0.02 
    <15 mL/min/1.73m2 f … … … 
  Urine dipstick proteinm 
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    negative 146 (73.4) 153 (69.9) 0.08 
    0.3g/L or more 53 (26.6) 66 (30.1) 0.08 
Abbreviations: ACE inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; GFR, glomerular 
filtration rate; IQR, interquartile range; NSAID, Non-steroidal anti-inflammatory drug; SD, standard deviation 
aData are presented as the number (percentage) of patients, unless otherwise reported. 
bStandardized difference describes differences between group means with respect to pooled standard deviation and indicates a 
meaningful difference if greater than 0.10 (10%).146,147,150 
cIncome was not available for 41 (2.8%) drug users and 36 (2.5%)  non-users. 
dLocation of residence was not available for less than five drug users and was available for all non-users. 
eComorbid conditions in the 5 years preceding the index date were considered, respectively. 
fNumber of patients with bipolar disorder, use of lithium, and estimated GFR <15mL/min/1.73m2 were too few (less than five) 
and were not available for the reasons of patient privacy. 
gCoronary artery disease includes diagnoses of angina and receipt of coronary artery bypass graft surgery and percutaneous 
coronary intervention. 
hDiabetes mellitus and were defined by use of any diabetic medication in the 6 months preceding the index date. 
iHypertension was defined by use of any antihypertensive medication in the 6 months preceding the index date. 
jMedication use in the 180 days preceding the index date were considered. 
kBaseline serum creatinine measurements were taken as a routine care at a median (IQR) of 83 (32-183) and 119 (50-208) days 
prior to the index date for the drug user and non-user groups, respectively.  
lEstimated GFR was calculated using the CKD-EPI equation153: 141 × min([Serum creatinine concentration in µmol/L/88.4]/k,1)a 
× max([serum creatinine concentration in µmol/L/88.4]/k,1)-1.209 × 0.993Age ×1.018 [if female] × 1.159 [if black]; k=0.7 if female 
and 0.9 if male; a=-0.329 if female and -0.411 if male; min=the minimum of serum creatinine concentration/k or 1; max=the 
maximum of serum creatinine concentration/k or 1. Information on race was not available in our data sources and all patients were 
assumed not to be of African Canadian race; African Canadians represented less than 5% of the population of Ontario in 2006.154 
mUrine dipstick protein measurements were available for 199 drug users and 219 non-users. 
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 Table 3: Potential reasons for AKI and all-cause mortality in atypical antipsychotic drug users and non-users 
 Events, No (%) Relative Risk 
(95% CI) 
Absolute Risk 
Difference 
(95% CI), % 
NNH 
(95% CI) Users (n=96,471) 
Non-Users 
(n=96,471) 
Potential reasons for AKIa 
  Hypotension 393 (0.41) 182 (0.19) 2.16 (1.81–2.57) 0.22 (0.17–0.27) 457 (374–588) 
  Acute urinary retention 340 (0.35) 158 (0.16) 2.15 (1.78–2.60) 0.19 (0.14–0.23) 530 (427–698) 
  Neuroleptic malignant 
syndrome/rhabdomyolysis 101 (0.10) 70 (0.07) 1.44 (1.06–1.96) 0.03 (0.01–0.06) 3112 (1704–17963) 
Acute myocardial infarction 629 (0.65) 471 (0.49) 1.34 (1.19–1.51) 0.16 (0.10–0.23) 611 (433–1036) 
  Ventricular arrhythmia 211 (0.22) 123 (0.13) 1.72 (1.37–2.14) 0.09 (0.05–0.13) 1096 (779–1849) 
All-cause mortality 
  All-cause mortality 6,688 (6.93) 2,658 (2.76) 2.68 (2.56–2.81) 4.18 (3.99–4.37) 24 (23–25) 
Abbreviations: AKI, acute kidney injury; CI, confidence interval; NNH, number need to harm 
aEvents (and the proportion of patients with an event) were assessed using hospital diagnosis codes. The true event rate is 
underestimated for some outcomes as the codes for the outcomes have high specificity, but low sensitivity. Similarly, NNH is 
underestimated for this reason. 
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 Table 4: The association between atypical antipsychotic drug use and hospitalization with AKI, examined in subgroups 
defined by evidence of CKD, antipsychotic drug type, antipsychotic drug dose, and residential status 
 
No. with Events/No. at Risk (%)a Relative Risk 
(95% CI) 
Interaction 
Test 
(P value) 
Absolute Risk 
Difference  
(95% CI), % 
NNH 
(95% CI) Users Non-Users 
Evidence of CKD 
  CKD 280/6,819 (4.11%) 156/6,819 (2.29%) 1.82 (1.49–2.22) 0.15 1.82 (1.23–2.41) 55 (41–82)   No CKD 742/89,652 (0.83%) 344/89,652 (0.38%) 2.16 (1.90–2.46) 0.44 (0.37–0.52) 225 (194–269) 
Antipsychotic Drug Type 
  Quetiapine 379/34,672 (1.09%) 202/34,672 (0.58%) 1.89 (1.59–2.24) 
0.13 
0.51 (0.38–0.65) 196 (155–267) 
  Risperidone 468/43,693 (1.07%) 232/43,693 (0.53%) 2.04 (1.74–2.39) 0.54 (0.42–0.66) 185 (152–237) 
  Olanzapine 175/18,106 (0.97%) 66/18,106 (0.36%) 2.65 (2.00–3.52) 0.60 (0.43–0.77) 166 (130–230) 
Antipsychotic Drug Doseb 
  High dose 386/34,089 (1.13%) 180/34,089 (0.53%) 2.16 (1.81–2.59) 0.49 0.60 (0.47–0.74) 165 (135–213)   Low dose 636/62,382 (1.02%) 320/62,382 (0.51%) 2.00 (1.75–2.29) 0.51 (0.41–0.60) 197 (166–244) 
Residential Status 
  Community 
  dwelling 740/73,408 (1.01%) 316/73,408 (0.43%) 2.37 (2.08–2.71) < 0.001 
0.58 (0.49–0.66) 173 (151–203) 
  Long-term  
  Care 282/23,063 (1.22%) 184/23,063 (0.80%) 1.53 (1.27–1.85) 0.42 (0.24–0.61) 235 (164–414) 
Abbreviations: AKI, acute kidney injury; CI, confidence interval; CKD, chronic kidney disease; NNH, number need to harm 
aAcute kidney injury (AKI) (and the proportion of patients with AKI) were assessed using a hospital diagnosis code. The true 
event rate of AKI is underestimated for some outcomes as the code for AKI has high specificity, but low sensitivity. Similarly, 
NNH is underestimated for this reason. 
bHigh dose was defined as: >25 mg/day quetiapine, >0.5mg/day risperidone, and >2.5mg/day olanzapine and low dose was 
defined as: ≤25 mg/day quetiapine, ≤0.5mg/day risperidone, and ≤2.5 mg/day olanzapine. 
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Chapter 6  
6 Discussion 
 
6.1 Summary and interpretation of study results 
Although previous case reports have attributed AKI to atypical antipsychotic drug use, 
their relationship had not been investigated.8–12 In this retrospective matched cohort study 
of older adults, we followed new atypical antipsychotic drug users and non-users for 90 
days to characterize the risk of AKI associated with the initiation of atypical 
antipsychotic drug use. We demonstrated that newly initiated atypical antipsychotic drug 
use versus non-use was associated with a higher risk of hospitalization with AKI in older 
adults. 
Although the precise mechanism of AKI from these drugs requires further elucidation, 
our results suggest that hypotension, acute urinary retention, neuroleptic malignant 
syndrome/rhabdomyolysis, and acute cardiac events might have biologically mediated the 
observed association between the drug use and AKI. First, AKI might have developed 
from decreased renal perfusion.13–18,33,59,78,93,95–97 The drugs have the ability to induce 
hypotension by antagonizing alpha-adrenergic receptors which are involved in the 
regulation of vascular contractility.78,93 Furthermore, it is plausible that the hemodynamic 
derangements and decreased renal perfusion that resulted from acute cardiac events might 
have precipitated AKI.31–33,59,106–115 Second, acute urinary retention induced by the drugs 
might have led to AKI.8,20,21,59,98,99,155 The drugs are able to block muscarinic 
acetylcholine receptors, which are present in the urinary tract and involved in 
micturition.8,98,99 Lastly, AKI might have occurred from the structural damage incurred 
by the myoglobin released from damaged muscles in patients suffering neuroleptic 
malignant syndrome/rhabdomyolysis following the drug use.9–12,22–30,101–104 The ability 
for the drugs to suddenly block dopamine receptors have been postulated to explain this 
adverse effect.22,30 The down-regulation of the dopaminergic neurons could have also 
resulted in the hyperactivity of the sympathetic nervous system and resultant muscle 
damage. 
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Patients with CKD are especially predisposed to AKI.37,52–54 In our study, the absolute 
risk difference in the incidence of hospitalization with AKI between atypical 
antipsychotic drug users and non-users were greater in patients with CKD compared to 
those without CKD. Patients with CKD should be warned about the potential risk of AKI 
and be closely monitored when commenced on atypical antipsychotic drug 
therapy.37,48,52–54 
The association found between atypical antipsychotic drug use and AKI was consistent in 
patients who received quetiapine, risperidone, or olanzapine.  
The antipsychotic drug dose did not influence the association between the drug use and 
AKI. A possible explanation for this observation would be that the starting dose was used 
to define high dose versus low dose in our study. Since dose titration is a common 
therapeutic strategy in older patients, the starting dose is unlikely to represent the end-
dose.78 An alternative speculation would be that the rate of dose titration rather than the 
absolute amount of dose influences the development of AKI.  
While an association between atypical antipsychotic drug use and hospitalization with 
AKI was observed in both community-dwellers and long-term care residents, the 
association was more pronounced in community-dwellers. This finding is consistent with 
a previous study that found the risk of short-term serious events associated with atypical 
antipsychotic drug use to be higher in community-dwellers than in long-term care 
residents.84 A possible explanation for this finding is less surveillance following 
treatments in older adults residing in the community compared to those living in long-
term care facilities. 
Our findings expand on accumulating evidences that have advised caution in the use of 
atypical antipsychotic drugs in older adults.3,4,31,32,83,84,116 In our study, atypical 
antipsychotic drug use versus non-use was also associated with a higher risk of all-cause 
mortality. This finding supports the federal advisory of the U.S. and Canada that warns of 
the risk of death associated with the drug use in older patients with dementia.3,4 In our 
observational study, the 90-day incidence of death was 6.9% in the drug users versus 
2.8% in the non-users. These rates similar to those presented by the U.S. Food and Drug 
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Administration from the analyses of placebo-controlled trials that included older patients 
(averaging 10 weeks in duration).3 In their analysis, the incidence of death was 4.5% in 
the drug-treated group versus 2.6% in the placebo group.3 The association between 
atypical antipsychotic drug use and short-term mortality has also been evidenced in a 
meta-analysis of randomized placebo-controlled trials (10 to 12 weeks in duration) and a 
previous population-based cohort study.83,116 
In our observational study, the incidence of hospitalization with hypotension was 0.41% 
in the atypical antipsychotic drug user group and 0.19% in the non-user group (i.e. RR of 
2.16 [95% CI 1.81–2.57]). In the analysis of two randomized placebo-controlled trials 
that included patients aged 55 years and older, the incidence of orthostatic hypotension 
was 5.5-fold higher in patients treated with an atypical antipsychotic drug compared to 
patients in the placebo group.13 Unlike our observational study, which used a hospital 
diagnosis code to identify hypotension (a code which is expected to be insensitive and to 
detect only severe forms of hypotension), the incidence of orthostatic hypotension in the 
analysis of two randomized trials was 17.9% (5 out of 28 patients) in the drug-treated 
group versus 3.2% (1 out of 31 patients) in the placebo group.13 
 
6.2 Study strengths and limitations 
Our study has several strengths. To our knowledge, this is the first population-based 
study that characterized the risk of AKI associated with atypical antipsychotic drug use. 
Furthermore, our study explored potential reasons why AKI may develop from the drug 
use. The population-based associations observed in our study were supported by the 
known biological effects of the drugs.8–30 The use of provincial healthcare administrative 
data on universal prescription drug coverage allowed us to accrue a large, representative 
sample of older adults who received atypical antipsychotic drugs. This enabled us to 
estimate the risk of less common but serious adverse drug events with high levels of 
precision and generalizability. Many previous population-based studies that examined the 
safety of atypical antipsychotic drugs in older adults only included those with 
dementia.31,83,84,128 In comparison, the inclusion of older patients with a variety of mental 
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disorders (schizophrenia or other psychotic disorder, bipolar disorder, and major 
depression and/or anxiety disorder) enabled the study results to be applicable to a wider 
range of patients. Finally, we employed a ‘new user’ design, which allows observational 
studies to mimic clinical trials in that patients are immediately followed from the time of 
treatment initiation.156 This method enabled us to reduce potential bias that may arise 
from accruing prevalent drug users who have survived initial periods of the 
pharmacotherapy.156 
Experimental studies provide the strongest evidence for whether or not an exposure has 
an effect on the risk of a disease.157 However, clinical trials are costly and the relatively 
small number of patients enrolled in the trials makes the estimation of risk for relatively 
rare adverse drug events difficult.131,158 Large observational studies can complement the 
findings of clinical trials by enabling the investigation of uncommon but important 
adverse drug events with adequate statistical power. Moreover, these observational 
studies can include vulnerable groups of patients who may be excluded from clinical 
trials and better reflect what occurs in routine clinical settings where treatments and 
monitoring are less regulated than in clinical trials.31,32,83,159,160  
A major concern of observational studies is the non-random distribution of exposure; in 
the case of our study, atypical antipsychotic drug use. The two groups being compared 
may be different on several characteristics including those that are risk factors for the 
outcomes of interest such as AKI.133 Despite achieving similarity in 29 baseline 
characteristics measured in the drug users and non-users, the concern for residual 
confounding cannot be eliminated, as there may be other unmeasured patient 
characteristics that differ between the drug user and non-user groups that may influence 
the risk of AKI. However, we propose residual confounding is unlikely to explain the 
entire observed association between the drug use and AKI in this study for several 
reasons. First, the association is supported by numerous case reports and the known 
biological effects of these drugs.8–30 It is difficult to conceive that a particular cause of 
AKI, such as neuroleptic malignant syndrome/rhabdomyolysis, in the 90-day follow-up 
(a risk observed in the present study) was not related to new atypical antipsychotic drug 
use.9–12,22–30 Second, the magnitude of the effect size was robust, with most point 
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estimates of RRs being greater than two. Even if the risk estimates are partly attenuated 
after accounting for unmeasured confounders, the results would still suggest that atypical 
antipsychotic drug-induced AKI is an important adverse drug event at the population-
level given the high prevalence and increasing incidence of prescriptions for the drugs in 
older adults.1,2  
In addition to the potential for residual confounding, our study has several other 
shortcomings. The absolute risk difference for some outcomes was underestimated 
because the hospital diagnosis codes for some conditions were insensitive.141,142 To 
address this concern for the primary outcome of AKI, we supplemented our findings and 
observed consistent results in a subpopulation with available serum creatinine 
measurements. We generalize our findings only to older adults, as reliable drug data was 
not available on patients under age 65 in our data sources. Although younger patients 
may be expected to have improved resistance to AKI, it is worth noting that the doses of 
atypical antipsychotic drugs used in younger patients are also generally higher than of 
those used in older patients.74 Moreover, our findings may be only applicable to the use 
of quetiapine, risperidone, and olanzapine; the most commonly used atypical 
antipsychotic drugs in Ontario.1,2 However, it remains prudent to use other atypical 
antipsychotic drugs cautiously as well (such as aripiprazole, ziprasidone, and 
paliperidone) as federal warnings for increased mortality extend to the entire drug 
class.3,4,155,161–169 
 
6.3 Study implications 
Our results suggest that AKI may result from atypical antipsychotic drug use and that the 
kidney injury may be mediated by hypotension, acute urinary retention, neuroleptic 
malignant syndrome/rhabdomyolysis, acute cardiac events. We propose the study results 
are sufficiently compelling that they should be acted on to help prevent adverse drug 
events. There should be judicious use of atypical antipsychotic drugs for managing 
behavioural symptoms of dementia, as the adverse effects of the drugs can offset 
potential benefits.170,171 Using these drugs for the management behavioural symptoms of 
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dementia are not an approved indication by regulatory authorities (with the exception of 
risperidone in Canada).3,4 Patients with CKD may be at the highest absolute risk of AKI 
from use of these drugs. When an atypical antipsychotic drug is initiated, patients, 
especially those with CKD, can be informed about the potential adverse effects of the 
drug. Preventative measures may include monitoring for a decrease in urine output, 
performing a bladder scan to check for retention of urine, and measuring serum creatinine 
and blood pressure in follow-up. If a patient does present to medical attention with AKI, 
this drug class can be considered as a potential cause of the kidney injury so that it can be 
discontinued to promote resolution. 
 
6.4 Recommendations for future studies 
Future studies are warranted to better characterize the risk of AKI associated with 
atypical antipsychotic drug use including potential reasons for the kidney injury. Future 
studies may benefit by employing improved tools to measure the outcomes, such as blood 
pressure measurement for the assessment of hypotension or post-void residual urine 
measurement for the assessment of acute urinary retention. Moreover, future studies 
should further investigate the association between the drug use and the outcomes by 
including younger drug users and newly emerging atypical antipsychotic drugs such as 
aripiprazole. 
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Appendices 
Appendix A: STROBE checklist121 
 Item 
No 
Recommendation Reported 
Title and abstract 1 (a) Indicate the study’s design with a 
commonly used term in the title or 
the abstract 
Abstract 
(b) Provide in the abstract an 
informative and balanced summary 
of what was done and what was 
found 
Abstract 
Introduction 
  Background/rationale 2 Explain the scientific background 
and rationale for the investigation 
being reported 
Chapter 1, 
2, 3, Figure 
1 
  Objectives 3 State specific objectives, including 
any pre-specified hypotheses 
Chapter 3 
Methods 
  Study design 4 Present key elements of study design 
early in the paper 
Chapter 4 
  Setting 5 Describe the setting, locations, and 
relevant dates, including periods of 
recruitment, exposure, follow-up, 
and data collection 
Chapter 4 
  Participants 6 (a) Give the eligibility criteria, and 
the sources and methods of selection 
of participants. Describe methods of 
follow-up 
Chapter 4, 
Figure 2 
(b) For matched studies, give 
matching criteria and number of 
exposed and unexposed 
Chapter 4, 
Figure 2, 
Appendix B 
  Variables 7 Clearly define all outcomes, 
exposures, predictors, potential 
confounders, and effect modifiers. 
Give diagnostic criteria, if applicable 
Chapter 2, 
Chapter 4, 
Appendix B, 
Appendix C 
  Data 
sources/measurement 
8 For each variable of interest, give 
sources of data and details of 
methods of assessment 
(measurement). Describe 
comparability of assessment methods 
if there is more than one group 
Chapter 4, 
Appendix B, 
Appendix C 
  Bias 9 Describe any efforts to address 
potential sources of bias 
Chapter 4, 
Chapter 6 
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  Study size 10 Explain how the study size was 
arrived at 
Chapter 4; 
based on 
availability 
of the data 
  Quantitative variables 11 Explain how quantitative variables 
were handled in the analyses. If 
applicable, describe which groupings 
were chosen and why 
Chapter 4 
  Statistical methods 12 (a) Describe all statistical methods, 
including those used to control for 
confounding 
Chapter 4 
(b) Describe any methods used to 
examine subgroups and interactions 
Chapter 4 
(c) Explain how missing data were 
addressed 
Not 
applicable 
(d) If applicable, explain how loss to 
follow-up was addressed 
Not 
applicable 
(e) Describe any sensitivity analyses Not 
applicable 
Results 
  Participants 13 (a) Report numbers of individuals at 
each stage of study—e.g. numbers 
potentially eligible, examined for 
eligibility, confirmed eligible, 
included in the study, completing 
follow-up, and analyzed 
Chapter 5, 
Figure 2 
(b) Give reasons for non-
participation at each stage 
Chapter 4, 
Figure 2 
  (c) Consider use of a flow diagram Figure 2 
  Descriptive data 14 (a) Give characteristics of study 
participants (e.g. demographic, 
clinical, social) and information on 
exposures and potential confounders 
Chapter 5, 
Table 1, 
Table 2 
(b) Indicate number of participants 
with missing data for each variable 
of interest 
Chapter 5, 
Table 1, 
Table 2 
(c) Summarize follow-up time (e.g. 
average and total amount) 
Chapter 5, 
Table 3 
  Outcome data 15 Report numbers of outcome events 
or summary measures over time 
Chapter 5, 
Table 3 
  Main results 16 (a) Give unadjusted estimates and, if 
applicable, confounder-adjusted 
estimates and their precision (e.g. 
95% confidence interval). Make 
clear which confounders were 
adjusted for and why they were 
Chapter 5, 
Table 3 
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included 
(b) Report category boundaries when 
continuous variables were 
categorized 
Chapter 4 
(c) If relevant, consider translating 
estimates of relative risk into 
absolute risk for a meaningful time 
period 
Chapter 5, 
Table 3, 
Table 4 
  Other analyses 17 Report other analyses done—e.g. 
analyses of subgroups and 
interactions, and sensitivity analyses 
Chapter 5, 
Table 4 
Discussion 
  Key results 18 Summarize key results with 
reference to study objectives 
Chapter 6 
  Limitations 19 Discuss limitations of the study, 
taking into account sources of 
potential bias or imprecision. 
Discuss both direction and 
magnitude of any potential bias 
Chapter 6 
  Interpretation 20 Give a cautious overall interpretation 
of results considering objectives, 
limitations, multiplicity of analyses, 
results from similar studies, and 
other relevant evidence 
Chapter 6 
  Generalizability 21 Discuss the generalizability (external 
validity) of the study results 
Chapter 6 
Other information 
  Funding 22 Give the source of funding and the 
role of the funders for the present 
study and, if applicable, for the 
original study on which the present 
article is based 
Acknowledg
ments 
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Appendix B: Coding definitions for demographics and comorbid conditions 
Variable Database Code 
Age RPDB  
Sex RPDB  
Income 
(neighbourhood 
income quintiles) 
Statistics 
Canada 
 
Location of residence Statistics 
Canada 
 
Residential status ODB  
Dementia CIHI-DAD ICD-9 2900, 2901, 2903, 2904, 2908, 2909, 
2948, 2949, 3310, 3311, 3312, 2941, 797 
ICD-10 F065, F066, F068, F069, F09, F00, 
F01, F02, F03, F051, G30, G31, R54 
OMHRS DSM-IV 29040, 29041, 29042, 29043, 29120, 
29282, 29410, 29411, 29480, 78090 
OHIP 290, 331, 797 
Schizophrenia or 
other psychotic 
disorder 
CIHI-DAD ICD-9 2950, 2951, 2952, 2953, 2954, 2955, 
2956, 2957, 2958, 2959, 2970, 2971, 2972, 
2973, 2978, 2979, 2980, 2981, 2983, 2984, 
2988, 2989 
ICD-10 F060, F062, F105, F107, F115, F117, 
F125, F127, F135, F137, F145, F147, F155, 
F157, F165, F167, F175, F177, F185, F187, 
F195, F197, F200, F201, F202, F203, F204, 
F205, F206, F208, F209, F220, F228, F229, 
F230, F231, F232, F233, F238, F239, F24, 
F250, F251, F252, F258, F259, F28, F29 
OMHRS DSM-IV 29130, 29150, 29211, 29212, 29381, 
29382, 29510, 29520, 29530, 29540, 29560, 
29570, 29590, 29710, 29730, 29880, 29890 
OHIP 291, 292, 295, 297, 298, Q021 
Bipolar disorder CIHI-DAD ICD-9 2960, 2961, 2964, 2965, 2966, 2967, 
2968 
ICD-10 F300, F301, F302, F308, F309, F310, 
F311, F312, F313, F314, F315, F316, F317, 
F318, F319 
OMHRS DSM-IV 29600, 29601, 29602, 29603, 29604, 
29605, 29606, 29640, 29641, 29642, 29643, 
29644, 29645, 29646, 29650, 29651, 29652, 
29653, 29654, 29655, 29656, 29660, 29661, 
29662, 29663, 29664, 29665, 29666, 29670, 
29680, 29689 
OHIP 296, Q020 
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Major depression 
and/or anxiety 
disorder 
CIHI-DAD ICD-9 2962, 2963, 3000, 3002, 3003, 3004, 
3091, 311 
ICD-10 F063, F064, F320, F321, F322, F323, 
F328, F329, F330, F331, F332, F333, F334, 
F338, F339, F341, F400, F401, F402, F408, 
F409, F410, F411, F412, F413, F418, F419, 
F420, F421, F422, F428, F429, F430, F431 
OMHRS DSM-IV 29189, 29284, 29289, 29383, 29384, 
29620, 29621, 29622, 29623, 29624, 29625, 
29626, 29630, 29631, 29632, 29633, 29634, 
29635, 29636, 30000, 30001, 30002, 30021, 
30022, 30023, 30029, 30030, 30040, 30113 
OHIP 311 
Chronic kidney 
disease 
CIHI-DAD ICD-9 4030, 4031, 4039, 4040, 4041, 4049, 
582, 583, 580, 581, 584, 585, 586, 587, 5880, 
5888, 5889, 5937 
ICD-10 E102, E112, E132, E142, I12, I13, 
N08, N18, N19 
OHIP 403, 585 
Cerebrovascular 
disease 
CIHI-DAD ICD-9 434, 436, 431, 4358, 4359 
ICD-10 H341, I630, I631, I632, I633, I634, 
I635, I638, I639, I629, I64, G45, I61 
Chronic liver disease CIHI-DAD ICD-9 4561, 4562, 070, 5722, 5723, 5724, 
5728, 573, 7824, V026, 2750, 2751, 7891, 
7895, 571 
ICD-10 B16, B17, B18, B19, I85, R17, R18, 
R160, R162, B942, Z225, E831, E830, K70, 
K713, K714, K715, K717, K721, K729, K73, 
K74, K753, K754, K758, K759, K76, K77 
OHIP 571, 573, 070, Z551, Z554 
Congestive heart 
failure 
CIHI-DAD ICD-9 425, 5184, 514, 428 
ICD-10 I500, I501, I509, I255, J81 
CCP 4961, 4962, 4963, 4964 
CCI 1HP53, 1HP55, 1HZ53GRFR, 
1HZ53LAFR, 1HZ53SYFR 
OHIP 428, R701, R702, Z429 
Coronary artery 
disease 
CIHI-DAD ICD-9 410 412, 413, 414, 4292, 4295, 4296, 
4297 
ICD-10 I20, I21, I22, I23, I24, I25, Z955, 
Z958, Z959, R931, T822 
CCP 4801, 4802, 4803, 4804, 4805, 481, 482, 
483 
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CCI 1IJ26, 1IJ27, 1IJ54, 1IJ57, 1IJ50, 1IJ76 
OHIP 410, 412, 413, R741, R742, R743, G298, 
E646, E651, E652, E654, E655, G262, Z434, 
Z448 
Diabetes mellitus ODB  
Hypertension ODB  
Peripheral vascular 
disease 
CIHI-DAD ICD-9 4402, 4408, 4409, 5571, 4439, 444 
ICD-10 I700, I702, I708, I709, I731, I738, 
I739, K551 
CCP 5125, 5129, 5014, 5016, 5018, 5028, 
5038 
CCI 1KA76, 1KA50, 1KE76, 1KG26, 
1KG50, 1KG57, 1KG76MI, 1KG87 
OHIP R787, R780, R797, R804, R809, R875, R815, 
R936, R783, R784, R785, E626, R814, R786, 
R937, R860, R861, R855, R856, R933, R934, 
R791, E672, R794, R813, R867, E649 
Prescribing physician ODB  
CCI, Canadian Classification of Health Interventions; CCP, Canadian Classification of 
Diagnostic, Therapeutic and Surgical Procedures; CIHI-DAD, Canadian Institute for 
Health Information Discharge Abstract Database; ICD-9, International Classification of 
Diseases, Ninth Revision; ICD-10, International Classification of Diseases, Tenth 
Revision; ODB, Ontario Drug Benefit; OHIP, Ontario Health Insurance Plan; OMHRS, 
Ontario Mental Health Reporting System; RPDB, Ontario’s Registered Persons 
Database 
 
  
 
70 
 
Appendix C: Coding definitions for hospitalized outcomes 
Outcome Database Code 
Primary outcome 
  Acute kidney injurya CIHI-DAD ICD-10 N17 
Secondary outcomes 
  Hypotensionb CIHI-DAD ICD-10 I95 
  Acute urinary retentionb CIHI-DAD R33 
  Neuroleptic malignant 
  syndrome/rhabdomyolysis 
CIHI-DAD ICD-10 G210, M628, T796 
  Acute myocardial 
infarctionc 
CIHI-DAD ICD-10 I21, I22 
  Ventricular arrhythmia CIHI-DAD ICD-10 I460, I469, I470, I472, I4900, 
I4901,  
CCI 1HZ09JAFS, 1HZ09JAJF, 
1HZ30JN, 1HZ30JY 
  All-cause mortalityd RPDB Vital status field 
Abbreviations: CCI, Canadian Classification of Health Interventions; CIHI-DAD, 
Canadian Institute for Health Information Discharge Abstract Database; ICD-10, 
International Classification of Diseases, Tenth Revision; RPDB, Ontario’s Registered 
Persons Database 
aValidation of the code for acute kidney injury was performed on approximately 39 000 
hospitalizations with linked laboratory measurements for serum creatinine. See 
Methods section for a description of the validation.141 
bUsing reabstracted information written in a patient’s chart as the reference standard, 
the code for hypotension and acute urinary retention has a sensitivity of 72% and 86%, 
and positive predictive value of 39% and 48%, respectively.142 This is a poor reference 
standard compared to patient blood pressure measurements and post-void residual urine 
volumes. 
cCode I21 (most responsible diagnosis) has a sensitivity of 89% and positive predictive 
value of 87%.142 
dAll-cause mortality has a sensitivity of 94% and specificity of 100%.143 
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